226 related articles for article (PubMed ID: 25911624)
21. Design and prediction of new anticoagulants as a selective Factor IXa inhibitor via three-dimensional quantitative structure-property relationships of amidinobenzothiophene derivatives.
Gao JS; Tong XP; Chang YQ; He YX; Mei YD; Tan PH; Guo JL; Liao GC; Xiao GK; Chen WM; Zhou SF; Sun PH
Drug Des Devel Ther; 2015; 9():1743-59. PubMed ID: 25848211
[TBL] [Abstract][Full Text] [Related]
22. Molecular modeling studies of [6,6,5] Tricyclic Fused Oxazolidinones as FXa inhibitors using 3D-QSAR, Topomer CoMFA, molecular docking and molecular dynamics simulations.
Xu C; Ren Y
Bioorg Med Chem Lett; 2015 Oct; 25(20):4522-8. PubMed ID: 26343829
[TBL] [Abstract][Full Text] [Related]
23. A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa.
Thakur R; Kumar A; Bose B; Panda D; Saikia D; Chattopadhyay P; Mukherjee AK
Biochimie; 2014 Oct; 105():149-58. PubMed ID: 25038567
[TBL] [Abstract][Full Text] [Related]
24. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Isobe Y; Furugohri T; Kanno H
Bioorg Med Chem Lett; 2007 Aug; 17(16):4683-8. PubMed ID: 17555959
[TBL] [Abstract][Full Text] [Related]
25. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of Isosteviol derivatives as FXa inhibitors.
Shi Y; Pan BW; Li WC; Wang Q; Wu Q; Pan M; Fu HZ
Bioorg Med Chem Lett; 2020 Jan; 30(2):126585. PubMed ID: 31859158
[TBL] [Abstract][Full Text] [Related]
27. A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa.
Kundu S; Wu S
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500804
[TBL] [Abstract][Full Text] [Related]
28. Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches.
Lagos CF; Segovia GF; Nuñez-Navarro N; Faúndez MA; Zacconi FC
Molecules; 2017 Sep; 22(10):. PubMed ID: 28937618
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.
Pandya V; Jain M; Chakrabarti G; Soni H; Parmar B; Chaugule B; Patel J; Jarag T; Joshi J; Joshi N; Rath A; Unadkat V; Sharma B; Ajani H; Kumar J; Sairam KV; Patel H; Patel P
Eur J Med Chem; 2012 Dec; 58():136-52. PubMed ID: 23124211
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
Xing J; Yang L; Zhou J; Zhang H
Bioorg Med Chem; 2018 Dec; 26(23-24):5987-5999. PubMed ID: 30446438
[TBL] [Abstract][Full Text] [Related]
33. Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa.
Núñez-Navarro NE; Santana FM; Parra LP; Zacconi FC
Curr Med Chem; 2019; 26(17):3175-3200. PubMed ID: 29376487
[TBL] [Abstract][Full Text] [Related]
34. Investigation of factor Xa inhibitors containing non-amidine S1 elements.
Franciskovich JB; Masters JJ; Tinsley JM; Craft TJ; Froelich LL; Gifford-Moore DS; Klimkowski VJ; Smallwood JK; Smith GF; Smith T; Towner RR; Weir LC; Wiley MR
Bioorg Med Chem Lett; 2005 Nov; 15(21):4838-41. PubMed ID: 16140530
[TBL] [Abstract][Full Text] [Related]
35. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.
Verhoef D; Visscher KM; Vosmeer CR; Cheung KL; Reitsma PH; Geerke DP; Bos MHA
Nat Commun; 2017 Sep; 8(1):528. PubMed ID: 28904343
[TBL] [Abstract][Full Text] [Related]
36. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity.
de Candia M; Fiorella F; Lopopolo G; Carotti A; Romano MR; Lograno MD; Martel S; Carrupt PA; Belviso BD; Caliandro R; Altomare C
J Med Chem; 2013 Nov; 56(21):8696-711. PubMed ID: 24102612
[TBL] [Abstract][Full Text] [Related]
38. A new C-type lectin (RVsnaclec) purified from venom of Daboia russelii russelii shows anticoagulant activity via inhibition of FXa and concentration-dependent differential response to platelets in a Ca²⁺-independent manner.
Mukherjee AK; Dutta S; Mackessy SP
Thromb Res; 2014 Nov; 134(5):1150-6. PubMed ID: 25281435
[TBL] [Abstract][Full Text] [Related]
39. Indoline derivatives II: synthesis and factor Xa (FXa) inhibitory activities.
Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Ozeki T; Fujimoto K
Chem Pharm Bull (Tokyo); 2007 Mar; 55(3):393-402. PubMed ID: 17329879
[TBL] [Abstract][Full Text] [Related]
40. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
